Werewolf Therapeutics (HOWL) Insider Trading & Ownership $0.92 +0.07 (+8.37%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.89 -0.03 (-3.48%) As of 04/17/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Werewolf Therapeutics (NASDAQ:HOWL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage21.10%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$4.10 MNumber OfInsiders Selling(Last 3 Years)0 Get HOWL Insider Trade Alerts Want to know when executives and insiders are buying or selling Werewolf Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HOWL Insider Buying and Selling by Quarter Werewolf Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/6/2023Ra Capital Management, L.P.DirectorBuy1,853,000$2.21$4,095,130.00 (Data available from 1/1/2013 forward) HOWL Insider Trading Activity - Frequently Asked Questions Who is on Werewolf Therapeutics's Insider Roster? The list of insiders at Werewolf Therapeutics includes Ra Capital Management, L.P.. Learn more on insiders at HOWL. What percentage of Werewolf Therapeutics stock is owned by insiders? 21.10% of Werewolf Therapeutics stock is owned by insiders. Learn more on HOWL's insider holdings. Werewolf Therapeutics Key ExecutivesDr. Daniel J. Hicklin Ph.D. (Age 60)Founder, CEO, President, Secretary & Director Compensation: $928.26kMr. Timothy W. Trost CPA (Age 66)CFO, Treasurer & Assistant Secretary Compensation: $662.99kDr. Randi Isaacs M.D. (Age 68)Chief Medical Officer Compensation: $702.43kDr. Chulani Karunatilake Ph.D. (Age 64)Chief Technology Officer Compensation: $343.43kMs. Ellen A. Lubman M.B.A. (Age 48)Chief Business Officer More Insider Trading Tools from MarketBeat Related Companies Lyell Immunopharma Insider Selling scPharmaceuticals Insider Selling Aclaris Therapeutics Insider Selling RAPT Therapeutics Insider Selling Greenwich LifeSciences Insider Selling 4D Molecular Therapeutics Insider Selling Nkarta Insider Selling Korro Bio Insider Selling Larimar Therapeutics Insider Selling ADC Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Beware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1 This page (NASDAQ:HOWL) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
